China NMPA Drug Inspection - Shandong Fangming Pharmaceutical Group Co., Ltd. - Norfloxacin capsules
China NMPA drug inspection for Shandong Fangming Pharmaceutical Group Co., Ltd. published April 28, 2017. Drug: Norfloxacin capsules. The Hubei Provincial Food and Drug Administration issued an announcement on April 28, 2017, detailing drug quality sampl
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Shandong Fangming Pharmaceutical Group Co., Ltd. published April 28, 2017. Drug: Norfloxacin capsules. The Hubei Provincial Food and Drug Administration issued an announcement on April 28, 2017, detailing drug quality sampl
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox